Mohammed Milhem
Holden Chair of Experimental Therapeutics, Melanoma Program Director at Holden Comprehensive Cancer Center, Clinical Professor · University of Iowa Health Care Medical Center
Credentials: · · ·
History
- Present
Holden Chair of Experimental Therapeutics, Melanoma at Holden Comprehensive Cancer Center, Clinical Professor · University of Iowa Health Care Medical Center
Research
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Journal of Clinical Oncology · 2015 · 2,112 citations
Improved survival with MEK inhibition in BRAF-mutated melanoma
New England Journal of Medicine · 2012 · 2,094 citations
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine · 2021 · 741 citations
31 papers · 3 as a fellow
22 papers · 13 as a fellow
- BT
16 papers
15 papers · 12 as a fellow
- AB
9 papers
- JR
9 papers · 7 as a fellow
- AH
8 papers
- AS
8 papers
Clinical trials
- 2026–2031
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
Principal investigator · Recruiting · Phase 1
Mohammed Milhem
- 2022–2026
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
Principal investigator · Active not recruiting · Phase 1, Phase 2
Mohammed Milhem
- 2022–2024
Chlorpromazine and Standard of Care in Glioblastoma
Principal investigator · Completed · Phase 1
Mohammed Milhem
- 2020–2027
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
Principal investigator · Active not recruiting · Phase 2
Donna Hammond, PhD